Dr Mark Buzza
Position:
- Director - Global Biomedical Research Programs, Movember Foundation
Credentials:
- PhD, MBA
Websites:
Biography:
Mark is the Director, Global Biomedical Research Programs at the Movember Foundation. Mark’s role is to foster synergies within the global prostate and testicular cancer research effort by ensuring clinicians, researchers and industry stakeholders collaborate and integrate their research activities. Mark leads a global team to deliver a multi-disciplinary cross-functional biomedical program portfolio to progress promising technologies and research to achieve optimal outcomes for patients.
Mark has worked across medical and clinical research, biotechnology, pharmaceuticals, not-for-profit and healthcare services and has held senior management and leadership roles within these sectors and has also worked with multinational organisations as a management consultant.
Mark has published widely in high-impact international medical and innovation journals, is a business mentor and a guest lecturer at RMIT University and is an Advisor to the Dublin-based Digital Health global collaboration platform – HealthXL.
Mark has a BSc (Hons) from La Trobe University, a PhD in Molecular Medicine from the University of Melbourne, an Executive MBA (with distinction) from the RMIT Graduate School of Business and Law and is a registered PRINCE2 Project Management Practitioner.
LinkedIn profile: https://www.linkedin.com/in/mark-buzza-7109a95/
Best publications:
Buzza, M (2016). Accelerating Men’s Health via Global Collaboration. Stanford Social Innovation Review 2016. May 5. https://ssir.org/articles/entry/accelerating_mens_health_via_global_collaboration
Bagot, K, Bove, L, Masser, B, Bednall, T & Buzza, M (2012) Perceived deterrents to being a plasmapheresis donor in a voluntary, non-remunerated environment. Transfusion 2012 Sep 24. doi: 10.1111/j.1537-2995.2012.03891.
Buzza, M, Marks, M, Capper, H, Cassin, E, Badcock, C, Reid, S, Kwok, M, Yang, H, Lee, J, Corrigan, C, Hartkopf-Theis, T, & Keller, A (2012), A prospective trial assessing the safety and efficacy of collecting up to 840 mL plasma in conjunction with saline infusion during plasmapheresis. Transfusion 2012 Feb 20. doi: 10.1111/j.1537-2995.2012.03561.
Bove, L, Bednall, T, Masser, B, & Buzza, M (2011), Understanding the apheresis donor in a voluntary, non-remunerated environment. Transfusion 51(11): 2411-24.
Buzza, M., Dagher, H., Wang, YY., Wilson, D., Babon, J., Cotton, R., & Savige, J. (2003). Mutations in the COL4A4 gene in thin basement membrane disease. Kidney International 63(2):447-53.
Buzza, M., Wang, YY., Dagher, H., Babon, J., Cotton, R., Powell, H., Dowling, J., & Savige, J. (2001). Identification of a COL4A4 mutation in Thin basement membrane disease (TBMD) previously described in autosomal recessive Alport syndrome. Kidney International 60:480-483.
Buzza, M., Wilson, D., & Savige, J. (2001). Segregation of haematuria in Thin basement membrane disease (TBMD) with haplotypes at the loci for autosomal recessive and X-linked Alport syndrome. Kidney International 59: 1670-1676.
Savige, J., Buzza, M., & Dagher, D. (2001). Haematuria in asymptomatic individuals. British Medical Journal April 21; 322 (7292): 942-943.
research and IP management, collaborative research, program management, biomarkers, CTCs, exosomes, biobanks..
